Clinical Study

Uccc-Hn-20-01- Phase 1B/II Trial Combining Pd1 Inhibition (Pembrolizumab) And Cesium 131 Brachytherapy With Salvage Surgery To Enhance Immunogenicity And Improve Local Control In Head And Neck Cancer

Posted Date: May 5, 2021

• Investigator: Chad Zender
• Specialties: Cancer, Head and Neck Cancer, Oncology
• Type of Study: Device & Drug

The main purpose of this study is to determine the safety and disease free survival of Perioperative PD-1 Inhibitor and Cesium-131 Interstitial Brachytherapy in patients with locally recurrent HNSCC eligible for salvage surgery.

Criteria:

Locally Recurrent Hnscc And Be Eligible For Salvage Surgery, If Patient Received Radiation Therapy In The Past, They Should Have Recovered From The Acute Toxicity To

Keywords:

Head And Cancer

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com